Subscription Center  


Venable Partner Paul Strain was quoted in the November 22 American Lawyer Litigation Daily regarding Merck's recent victory in a jury verdict over claims that its osteoporosis drug Fosamax causes jawbone necrosis.

Strain, who represents Merck, argued that Fosamax was thoroughly vetted before gaining U.S. Food & Drug Administration approval, and that the plaintiff's smoking habit, dental problems, and other medications may have contributed to her disease.